Ivan Liadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ivan Liadi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Bot
Capstan Therapeutics, San Diego, USA
1 shared publication - Ali Rezvan
William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA
1 shared publication - Ankit Mahendra
William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA
1 shared publication Darren Heeke
Kite, a Gilead company, Santa Monica, California, USA
1 shared publication- Francisco Vega
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
1 shared publication - Gabrielle Romain
William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (17)
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses
The in vivo persistence of adoptively transferred T cells is predictive of antitumor response. Identifying functional properties of infused T cells that lead to in vivo persistence and tumor eradication has remained elusive. We profiled CD19-specific chimeric antigen receptor (CAR) T cells as the infusion products used to treat large B cell lymphomas using high-throughput single-cell technologies based on time-lapse imaging microscopy in nanowell grids (TIMING), which integrates killing, cytokine secretion, and transcriptional profiling. Our results show that the directional migration of CD19-specific CAR T cells is correlated with multifunctionality. We showed that CD2 on T cells is associated with directional migration and that the interaction between CD2 on T cells and CD58 on lymphoma cells accelerates killing and serial killing. Consistent with this, we observed that elevated CD58 expression on pretreatment tumor samples in patients with relapsed or refractory large B cell lymphomas treated with CD19-specific CAR T cell therapy was associated with complete clinical response and survival. These results highlight the importance of studying dynamic T cell–tumor cell interactions in identifying optimal antitumor responses.
- 1 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (17)
Open AccessMultidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses
The in vivo persistence of adoptively transferred T cells is predictive of antitumor response. Identifying functional properties of infused T cells that lead to in vivo persistence and tumor eradication has remained elusive. We profiled CD19-specific chimeric antigen receptor (CAR) T cells as the infusion products used to treat large B cell lymphomas using high-throughput single-cell technologies based on time-lapse imaging microscopy in nanowell grids (TIMING), which integrates killing, cytokine secretion, and transcriptional profiling. Our results show that the directional migration of CD19-specific CAR T cells is correlated with multifunctionality. We showed that CD2 on T cells is associated with directional migration and that the interaction between CD2 on T cells and CD58 on lymphoma cells accelerates killing and serial killing. Consistent with this, we observed that elevated CD58 expression on pretreatment tumor samples in patients with relapsed or refractory large B cell lymphomas treated with CD19-specific CAR T cell therapy was associated with complete clinical response and survival. These results highlight the importance of studying dynamic T cell–tumor cell interactions in identifying optimal antitumor responses.